Watch the replay of How I Think, How I Treat: Individualizing RCC Therapy in the Era of Immuno-Oncology, that was held on Thursday, November 5, 2020, is now available here.
Multimodality Therapy for Locally Advanced RCC Session
Palliation of the Unresectable Kidney Mass with Systemic Therapy
Presented by: Elizabeth Wulff-Burchfield, MD
Imaging for Locally Advanced RCC (Node and Thrombus)
Presented by: Ivan Pedrosa, MD, PhD
Image Based Local Therapy for Oligometastatic Disease
Presented by: Rahul Sheth, MD
Non-Clear Cell RCC Session
Management of Multifocal Non-Clear Cell RCC
Presented by Mark Ball, MD
NRF2 and biallelic FH inactivation
Presented by: Aikseng Ooi, PhD
Response to Systemic Therapy in Patients with Metastatic Fumarate Hydratase (FH) Deficient RCC
Presented by: Jack Gleeson, MD
Pilot Study of Tremelimumab With or Without Cryoablation in Patients with mRCC
Presented by: Matthew Campbell, MD, MS
Immunotherapy and Emerging Therapies for RCC
Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC)
Presented by: Alex Chehrazi-Raffle, MD
Nivolumab 6 mg/kg plus ipilimumab 1 mg/kg (N6I1) every 8 weeks (Q8W) alternating with nivolumab 480 mg Q8W for first-line (1L) advanced renal cell carcinoma (aRCC): safety and efficacy from CheckMate 920
Presented by: Johanna Bendell, MD
Nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy
Presented by: Nizar Tannir, MD
Association of the Neutrophil to Eosinophil Ratio with Response to Ipilimumab/Nivolumab in Metastatic Renal Cell Carcinoma
Presented by: Matthew Tucker, MD
Metabolism as a Target for RCC Session
Metabolic Adaptations in RCC and the Tumor Microenvironment
Presented by: Ed Reznik, PhD
Chromatin Dysregulation and ccRCC
Presented by: Lauren Banaszynski, PhD
Anti-Tumor Activity of Small Molecule Glutaminase Inhibitors: Role of Telaglenastat (CB-839) in RCC
Presented by: Nizar Tannir, MD
Metabolic gene signature as biomarker for recurrence in localized clear cell RCC
Presented by: Shuchi Gulati, MD
Multimodality Therapy for Metastatic RCC
IKCS 2020 Keynote Address
New Therapies for Kidney Cancer Based on Studies of the Von Hippel-Lindau Tumor Suppressor Gene
Presented by: William G. Kaelin Jr., MD
Top Abstract Session
Associations between serum cytokine levels and gut microbiota composition in metastatic renal cell carcinoma
Presented by: Alex Chehrazi-Raffle, MD
Radiomic features of renal cell carcinoma metastatic sites can predict BAP1 mutation
Presented by: Luis Meza, MD
Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC)
Presented by: Sumanta Pal, MD
An integrated study of spatial dynamics and genomic alterations in renal cell carcinoma evolution
Presented by: Yue Zhao, PhD
Lunch by the WoodFire
Treating Kidney Cancer in a Pandemic
Treating Kidney Cancer in a Pandemic Supplementary Videos
Surgical Triage During COVID-19
Presented by: Brian Shinder, MD
A Patient’s Perspective
Interview with Megan Conley
Lessons from COVID-19: Evolution of Clinical Practice for Systemic Therapy and Clinical Research
Presented by: Martin Voss, MD
Delaying Surgery for Clinical T1b-T2bN0M0 Renal Cell Carcinoma: Oncologic Implications in the COVID-19 Era and Beyond
Presented by: Arnav Srivastava, MD